TORIDE

TORIDE acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na+/K+/2CI-- carrier system. It increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance.

The bioavailability of TORIDE is approximately 80%, with little inter subject variation. The drug is absorbed with little first-pass metabolism, and the serum concentration reaches its peak (Cmax) within 1 hour after oral administration. Simultaneous food intake delays the time to Cmax by about 30 minutes, but overall bioavailability (AUC) and diuretic activity are unchanged. The volume of distribution of TORIDE is 12 liters to 15 liters in normal adults or in patients with mild to moderate renal failure or congestive heart failure. In patients with hepatic cirrhosis, the volume of distribution is approximately doubled. The elimination half-life of TORIDE is approximately 3.5 hours

Hypertension: 2.5-5 mg once daily. Maximum dose is 5 mg once daily Edema in patient with hepatic cirrhosis: 5-10 mg once daily Edema: 5 mg once daily

TORIDE 10/ TORIDE 20 are available as blister strip of 10 tablets in a box of 10 x 10s